Global pharmaceutical leader Lupin Limited today commemorated the inauguration of its new corporate offices at 100 Somerset Corporate Blvd in Bridgewater marking a significant expansion of its presence in the state.
New Jersey Gov. Phil Murphy and Somerset County Commissioner Deputy Director Melonie Marano attended the ribbon-cutting ceremony alongside Lupin executives, including CEO Vinita Gupta and President, U.S. Generics, Spiro Gavaris.
The new office space, spanning approximately 18,000 square feet, will accommodate various corporate functions, including commercial, HR, finance, legal, marketing, business development, and R&D. Lupin first established its footprint in the state in 2016 with a manufacturing facility in Somerset.
Murphy praised the company’s investment, stating, “Lupin’s continued investments in New Jersey, evidenced by this expansion in Bridgewater, are fully aligned with my administration’s priorities: strengthening the state’s robust pharmaceutical industry, driving economic growth, and creating skilled jobs for our residents.”
Vinita Gupta, CEO of Lupin, emphasized the strategic importance of the location. “New Jersey is a stronghold for the biopharmaceutical industry, and our operations in the state… have been an important part of our U.S. growth and expansion. This foundation enables us to drive innovation and provide access to affordable, high-quality medications nationwide.”
Lupin’s New Jersey-based workforce currently exceeds 300 employees, with plans for continued growth. Spiro Gavaris, president, U.S. Generics, noted that the state “offers a robust pool of talented professionals across all facets of the life sciences sector, and we look forward to creating opportunities for their contributions.”
The expansion underscores Lupin’s broader long-term commitment to the U.S. health care ecosystem, following its recent announcement to build a state-of-the-art manufacturing facility in Coral Springs, Florida, dedicated to U.S. production of critical respiratory therapies.
